TF and neoplasm: Similarly, the in vivo tumor growth inhibition efficacy of anti-TF-NC-6300 was superior to NC-6300 in BxPC3 xenografts, but not in the SUIT2 xenograft model, demonstrating the enhanced antitumor effect of anti-TF-NC-6300 in the high-TF-expressing tumor [163].